Exploration of brain energy demand and neuronal aging: implications for tauopathies, neuroprotection

Jesús Avila , Félix Hernández

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004166

PDF (1671KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004166 DOI: 10.37349/ent.2026.1004166
Mini Review
research-article
Exploration of brain energy demand and neuronal aging: implications for tauopathies, neuroprotection
Author information +
History +
PDF (1671KB)

Abstract

The link between brain energy consumption and neuronal aging has been explored at the cellular and molecular levels. The brain is described as a “selfish organ”, as previously indicated in recent publications, demanding energy from peripheral organs to avoid a reduction of its energy expenditure. Aging is the main risk factor for neurodegenerative disorders, like tauopathies, related to neuronal energy changes. Thus, preventing, delaying, or reversing those changes should be a suitable way to carry out neuroprotection. Finally, possible therapies using as targets neuronal proteins like folate receptor alpha, GDF15 receptor, or tau protein, which are related to mitochondrial function and dysfunction, are proposed.

Keywords

neuronal aging / energy supply / tauopathies / FRα / GDF15

Cite this article

Download citation ▾
Jesús Avila, Félix Hernández. Exploration of brain energy demand and neuronal aging: implications for tauopathies, neuroprotection. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004166 DOI:10.37349/ent.2026.1004166

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Oh HS, Le Guen Y, Rappoport N, Urey DY, Farinas A, Rutledge J, et al. Plasma proteomics links brain and immune system aging with healthspan and longevity. Nat Med. 2025; 31: 2703-11.

[2]

Andreone BJ, Lacoste B, Gu C. Neuronal and vascular interactions. Annu Rev Neurosci. 2015; 38: 25-46.

[3]

Dienel GA, Schousboe A, McKenna MC, Rothman DL. A tribute to Leif Hertz: The historical context of his pioneering studies of the roles of astrocytes in brain energy metabolism, neurotransmission, cognitive functions, and pharmacology identifies important, unresolved topics for future studies. J Neurochem. 2024; 168: 461-95.

[4]

McKenna MC. Glutamate pays its own way in astrocytes. Front Endocrinol (Lausanne). 2013; 4: 191.

[5]

Pulido C, Ryan TA. Synaptic vesicle pools are a major hidden resting metabolic burden of nerve terminals. Sci Adv. 2021; 7:eabi9027.

[6]

Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012; 75: 762-77.

[7]

Polsky LR, Rentscher KE, Carroll JE. Stress-induced biological aging: A review and guide for research priorities. Brain Behav Immun. 2022; 104: 97-109.

[8]

Shafqat A, Khan S, Omer MH, Niaz M, Albalkhi I, AlKattan K, et al. Cellular senescence in brain aging and cognitive decline. Front Aging Neurosci. 2023; 15: 1281581.

[9]

Lee YH, Park JY, Lee H, Song ES, Kuk MU, Joo J, et al. Targeting Mitochondrial Metabolism as a Strategy to Treat Senescence. Cells. 2021; 10: 3003.

[10]

Na D, Zhang Z, Meng M, Li M, Gao J, Kong J, et al. Energy Metabolism and Brain Aging: Strategies to Delay Neuronal Degeneration. Cell Mol Neurobiol. 2025; 45: 38.

[11]

Otero MG, Henao-Romero N, Krysak TM, Vu-Lu MT, Morales OOM, Momeni Z, et al. Hyperglycemia-induced mitochondrial abnormalities in autonomic neurons via the RAGE axis. Sci Rep. 2025; 15: 25231.

[12]

Kim DH, Jo HY, Oh YJ, Lim JR, Chae CW, Jung YH, et al. Folate receptor 1 activation suppresses high glucose-induced amyloidogenesis in neurons via STAT3/Nrf2 pathway-dependent mitigation of mitochondrial oxidative stress. Biomed Pharmacother. 2026; 196: 119074.

[13]

Shaulson ED, Cohen AA, Picard M. The brain-body energy conservation model of aging. Nat Aging. 2024; 4: 1354-71.

[14]

Kwon D. How your brain controls ageing-and why zombie cells could be key. Nature. 2025; 642: 563-5.

[15]

Herrup K. The involvement of cell cycle events in the pathogenesis of Alzheimer’s disease. Alzheimers Res Ther. 2010; 2: 13.

[16]

Barrio-Alonso E, Hernández-Vivanco A, Walton CC, Perea G, Frade JM. Cell cycle reentry triggers hyperploidization and synaptic dysfunction followed by delayed cell death in differentiated cortical neurons. Sci Rep. 2018; 8: 14316.

[17]

Chiariello A, Valente S, Pasquinelli G, Baracca A, Sgarbi G, Solaini G, et al. The expression pattern of GDF15 in human brain changes during aging and in Alzheimer's disease. Front Aging Neurosci. 2023; 14: 1058665.

[18]

Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkjær SB, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017; 23: 1158-66.

[19]

Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017; 23: 1150-7.

[20]

Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017; 550: 255-9.

[21]

Chen CY, Wang Z, Hong CG, Tan YJ, Duan YX, Luo Y, et al. Brain neuron-derived WDFY1 induces bone loss. Nat Aging. 2026; 6: 329-48.

[22]

Xue XH, Tao LL, Su DQ, Guo CJ, Liu H. Diagnostic utility of GDF15 in neurodegenerative diseases: A systematic review and meta-analysis. Brain Behav. 2022; 12: e2502.

[23]

Dedovic K, Duchesne A, Andrews J, Engert V, Pruessner JC. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage. 2009; 47: 864-71.

[24]

Ulloa L. Electroacupuncture activates neurons to switch off inflammation. Nature. 2021; 598: 573-4.

[25]

Castrillon G, Epp S, Bose A, Fraticelli L, Hechler A, Belenya R, et al. An energy costly architecture of neuromodulators for human brain evolution and cognition. Sci Adv. 2023; 9: eadi7632.

[26]

Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004; 84: 361-84.

[27]

Hu W, Wu F, Zhang Y, Gong CX, Iqbal K, Liu F. Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Front Aging Neurosci. 2017; 9: 311.

[28]

Majounie E, Cross W, Newsway V, Dillman A, Vandrovcova J, Morris CM, et al. Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging. 2013; 34: 1922.e7-12.

[29]

Mooraj Z, Salami A, Campbell KL, Dahl MJ, Kosciessa JQ, Nassar MR, et al. Toward a functional future for the cognitive neuroscience of human aging. Neuron. 2025; 113: 154-83.

[30]

Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001; 24: 1121-59.

[31]

Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, et al. Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol. 2009; 174: 228-38.

[32]

Riessland M, Ximerakis M, Jarjour AA, Zhang B, Orr ME. Therapeutic targeting of senescent cells in the CNS. Nat Rev Drug Discov. 2024; 23: 817-37.

[33]

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76.

[34]

Abad M, Mosteiro L, Pantoja C, Cañamero M, Rayon T, Ors I, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013; 502: 340-5.

[35]

Ocampo A, Reddy P, Martinez-Redondo P, Platero-Luengo A, Hatanaka F, Hishida T, et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell. 2016; 167: 1719-33.e12.

[36]

Kim J, Lengner CJ, Kirak O, Hanna J, Cassady JP, Lodato MA, et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells. 2011; 29: 992-1000.

[37]

Rodríguez-Matellán A, Alcazar N, Hernández F, Serrano M, Ávila J. In Vivo Reprogramming Ameliorates Aging Features in Dentate Gyrus Cells and Improves Memory in Mice. Stem Cell Reports. 2020; 15: 1056-66.

[38]

Hernandez-Benitez R, Wang C, Shi L, Ouchi Y, Zhong C, Hishida T, et al. Intervention with metabolites emulating endogenous cell transitions accelerates muscle regeneration in young and aged mice. Cell Rep Med. 2024; 5: 101449.

[39]

Antón-Fernández A, Cauchola RP, Hernández F, Ávila J. Hippocampal rejuvenation by a single intracerebral injection of one-carbon metabolites in C57BL6 old wild-type mice. Aging Cell. 2025; 24: e14365.

[40]

Antón-Fernández A, Cuadros R, Peinado-Cahuchola R, Hernández F, Avila J. Role of folate receptor α in the partial rejuvenation of dentate gyrus cells: Improvement of cognitive function in 21-month-old aged mice. Sci Rep. 2024; 14: 6915.

[41]

Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013; 500: 486-9.

[42]

Boshnjaku V, Shim KW, Tsurubuchi T, Ichi S, Szany EV, Xi G, et al. Nuclear localization of folate receptor alpha: a new role as a transcription factor. Sci Rep. 2012; 2: 980.

[43]

Mohanty V, Shah A, Allender E, Siddiqui MR, Monick S, Ichi S, et al. Folate Receptor Alpha Upregulates Oct4, Sox2 and Klf4 and Downregulates miR-138 and miR-let-7 in Cranial Neural Crest Cells. Stem Cells. 2016; 34: 2721-32.

[44]

Gonzalez T, Muminovic M, Nano O, Vulfovich M. Folate Receptor Alpha-A Novel Approach to Cancer Therapy. Int J Mol Sci. 2024; 25: 1046.

[45]

Hulin-Curtis SL, Davies JA, Nestić D, Bates EA, Baker AT, Cunliffe TG, et al. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Ther. 2020; 27: 785-98.

[46]

Anton-Fernandez A, Domene-Serrano I, Cuadros R, Peinado-Cahuchola R, Sanchez-Pece M, Hernandez F, et al. Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery. ACS Omega. 2025; 10: 13236-50.

[47]

Jeffery G, Fosbury R, Barrett E, Hogg C, Carmona MR, Powner MB. Longer wavelengths in sunlight pass through the human body and have a systemic impact which improves vision. Sci Rep. 2025; 15: 24435.

[48]

Bieri G, Pratt KJB, Fuseya Y, Aghayev T, Sucharov J, Horowitz AM, et al. Liver exerkine reverses aging- and Alzheimer’s-related memory loss via vasculature. Cell. 2026; 189: 1499-516.e25.

[49]

Muzaffar S, Tyagi A, Pugazhenthi S. Therapeutic Potential of Irisin in Neurodegenerative Diseases. Int J Mol Sci. 2025; 26: 11348.

[50]

Arosio B, Picca A. Irisin and the muscle-brain axis: Mechanisms and translational potential. Exp Gerontol. 2026; 214: 113028.

[51]

Trandafir DM, Dumitru C, Zamfirache F, Prundaru GN, Ciobanu CA, Radu BM, et al. Intermittent Theta Burst Stimulation for Major Depressive Disorder with Comorbid Anxiety: A Systematic Review of Clinical Efficacy and Predictors of Response. Brain Sci. 2026; 16: 167.

[52]

van Rooij SJH, Arulpragasam AR, McDonald WM, Philip NS. Accelerated TMS - moving quickly into the future of depression treatment. Neuropsychopharmacology. 2024; 49: 128-37.

[53]

Musk E ; Neuralink. An Integrated Brain-Machine Interface Platform With Thousands of Channels. J Med Internet Res. 2019; 21: e16194.

[54]

Scheiblich H, Eikens F, Wischhof L, Opitz S, Jüngling K, Cserép C, et al. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes. Neuron. 2024; 112: 3106-25.e8.

[55]

Du S, Long Q, Zhou Y, Fu J, Wu H, Yang L, et al. Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson’s disease models. Cell. 2026; 189: 2821-33.e23.

[56]

Avila J. Delaying Brain Aging or Decreasing Tau Levels as Strategies to Prevent Alzheimer’s Disease: In Memoriam of Mark A. Smith. J Alzheimers Dis. 2024; 100: S265-70.

[57]

Sun M, Lin J, Li S. Extracellular tau oligomers exert neurocytotoxicity by triggering mitochondrial dysfunction. J Alzheimers Dis. 2026; 110: 409-25.

[58]

DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017; 9: eaag0481.

[59]

Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther. 2014; 6: 44.

[60]

Miller LVC, Papa G, Vaysburd M, Cheng S, Sweeney PW, Smith A, et al. Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function. Cell. 2024; 187: 5967-80.e17.

[61]

Canet G, Lucey BP, Blessing EM, Planel E. Lifelong heat exposure as a potential contributor to Alzheimer’s disease resilience. J Alzheimers Dis. 2026; 111: 541-4.

[62]

Prevot V, Dehouck B, Sharif A, Ciofi P, Giacobini P, Clasadonte J. The Versatile Tanycyte: A Hypothalamic Integrator of Reproduction and Energy Metabolism. Endocr Rev. 2018; 39: 333-68.

[63]

Sauvé F, Martinez-Gómez R, Mbouamboua Y, Ternier G, Nampoothiri S, Dupré E, et al. Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology. Cell Press Blue. 2026; 1: 100003.

[64]

Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, et al. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases. J Exp Clin Cancer Res. 2019; 38: 125.

[65]

Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, et al. Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015; 78: 814-23.

[66]

Castillo-Casaña Y, Arias C, Coria R. Tau-Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential. Cell Mol Neurobiol. 2025; 46: 3.

[67]

Szabo L, Eckert A, Grimm A. Insights into Disease-Associated Tau Impact on Mitochondria. Int J Mol Sci. 2020; 21: 6344.

[68]

Torres AK, Rivera BI, Polanco CM, Jara C, Tapia-Rojas C. Phosphorylated tau as a toxic agent in synaptic mitochondria: implications in aging and Alzheimer’s disease. Neural Regen Res. 2022; 17: 1645-51.

PDF (1671KB)

20

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉